Advance Cutting-Edge Research and Development with Next-Generation Targeted & Immune Therapies (mono & combination) and Learn How to Best Utilize them with Precision Oncology
The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies, either in combination or monotherapies.
Arriving at a critical point for the NSCLC drug development field, as checkpoint inhibitors are on the brink of entering the perioperative setting and the approval of novel bispecifics with dual oncogenic targeting, this forum will enable you to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards.
Network with 100+ executive biopharma leaders over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
View the event guide now to learn more!
The Excitement is Building:
"The Non-Small Cell Lung Cancer Summit will be an important venue to learn more about the latest developments in lung cancer, including the emerging new treatments, and some of the informative new science."
Tony Jarkowski, Development Lead, Bristol-Myers Squibb
"The summit is an excellent lineup of talks and speakers. There have been rapid practice changing advances in NSCLC and the summit is a great way to stay abreast of the progress and cutting-edge science."
Kelly Covello, PHD, Head of Medical Affairs, Mirati Therapeutics Inc.
Expert Speaker Faculty Includes:
Vice President, Clinical Research Lead, External Collaborations Oncology Early Development
Merck and Co
Head of Clinical, Late Development Oncology R&D
AstraZeneca & European Commission’s Mission for Cancer, Board Member
Executive Director, Early Development Program Lead
Bristol Myers- Squibb
What Will You Learn?
Knowledge gained from the current EGFR-TKI successes and implementing it into strategies for improvement, best application strategies and potential combination partners with AstraZeneca, Puma Biotechnology, Cullinan Oncology and Takeda
The potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie, Merus, Black Diamond, AOM Biosciences and Mirati Therapeutics.
The exciting advancements in the NSCLC rare mutations space, with the novel therapies in targeting BRAF, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals, Elevation Oncology and Boeringer Ingelheim.
The power of the immune system to treat NSCLC by delving into the current best, novel targets and combination strategies to improve patent outlook with Merck & Co, Immutep, BerGenBio and Bristol-Myers Squibb.
The efficacy of companion diagnostics and look to the future of early disease detection, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS, Takeda, Novartis, BloodPAC and Amgen.